Click here to close now.




















Welcome!

News Feed Item

Microfluidic Technologies: Biopharmaceutical and Healthcare Applications 2013-2023

LONDON, March 10, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

Microfluidic Technologies: Biopharmaceutical and Healthcare Applications 2013-2023


Report Details

Microfluidics - how to find trends, opportunities and revenue prospects

Do you want to assess the potential of microfluidic technologies? Visiongain's new report gives you revenue predictions there from 2013, helping you stay ahead. You find financial data, trends, opportunities, and outlooks.

In that work you see forecasted sales to 2023 at overall world market, submarket (application), and national level. You assess those trends and technologies for life sciences, pharmaceuticals, medical devices, and in vitro diagnostics.

Analysis of what shapes the microfluidics industry and determines its potential

Discover, then, what the future holds for microfluidics and its applications. Read on to explore that industry and see what its future market could be worth.

Forecasts to 2023 and other analyses show you commercial opportunities

Besides revenue forecasting to 2023, you see financial results, growth rates, and market shares. You assess quantitative and qualitative analysis, business news, outlooks, and developments (R&D). You also gain 48 tables, 46 charts, and two interviews.

Our work lets you investigate the most promising and lucrative parts of microfluidics, helping you stay ahead in knowledge. Finding data you need there just got easier.

Now see how you can benefit your research, analyses, and decisions, also saving time.

Prospects for the world market and submarkets

Our new report shows revenue to 2023 for the overall world market. It also shows you individual forecasts of 11 microfluidic submarkets. Find revenues to 2023 for these applications:
• In vitro diagnostics - with sub-forecasts for clinical diagnostics, point of care (POC) diagnostics, analytical devices, and other products
• Pharmaceutical and life science research - with sub-forecasts for genomics, proteomics, cell-based assays, and other products
• Drug delivery.

How will the microfluidics market expand? Which parts will most prosper? There you assess potential for sales.

Our study also discusses what stimulates and restrains that market. That analysis helps you identify potential and find ways for your business to benefit.

You find geographical revenue predictions too.

Forecasts of national markets for microfluidic technologies

In developed and developing countries, many sales opportunities for developers and producers of those technologies will occur from 2013. See where and how.

Our analyses show you individual revenue forecasts to 2023 for nine national markets and a regional block:
• US
Japan
Germany, France, UK, Italy, and Spain (EU5)
• EU (grouped regional forecast)
India and China.

There you find potential for the technology. Pharma and diagnostics companies face many opportunities worldwide. Our study explains, discussing crucial issues.

Developments and opportunities affecting microfluidics

Our report discusses issues and events affecting that industry and market from 2013:
• Products in development - R&D and expanding applications
• Microfluidic technologies and products available
• Lab-on-a-chip technology, with wide range of biological uses
• Production of devices - manufacturing issues
• Regulation of microfluidic devices - the US and Europe.

That study also discusses other aspects of the field, including these:
• Academia and industry - gaps and connections
• Demand for advanced drug delivery methods
• Microfluidics benefitting the biologics industry
• Drug development - including genomics, proteomics, and cell-based assays
• Delivery of drugs and vaccines - including microneedles, micropumps, and inhalers
• Personalised medicine and stem cells.

There, you explore that industry's strengths, weaknesses, opportunities, and threats. You see what stimulates and restrains technology and business.

See, then, what the future holds.

Prominent companies in that biomedical field and its 2017 market value

What happens next? Our study predicts the world market for microfluidics will reach $3.5bn in 2017 - with strong growth - and expand further to 2023. See how high revenues can go.

That work shows you what technologies, products, and organisations hold greatest potential. Our analysis investigates these companies and many others:
• Agilent Technologies
• PerkinElmer
• Cepheid
• Fluidigm Corporation.

In our study you find 192 organisations covered. Also, you read two interviews with authorities in that industry. See what shapes it, discovering what participants do and say.

Microfluidic technologies hold great potential for investment, development, and revenue growth from 2013. You see how they can progress, benefiting companies.

Eight ways Microfluidic Technologies: Biopharmaceutical and Healthcare Applications 2013-2023 helps you

To sum up, our analysis gives you the following knowledge:
• Revenue to 2023 for the world microfluidics market - discover that industry's overall sales potential
• Revenues to 2023 for 11 world-level submarkets - investigate the potential of its applications, finding the most promising places for investments and revenues
• Forecasts to 2023 for 9 national markets in North America, Europe, and Asia - find the best countries for revenues and potential growth
• Discussions and data for companies - hear about developers and manufacturers' activities, capabilities, results, and outlooks
• Review of R&D and prospects for market expansion - investigate developments, exploring possibilities for technological and commercial advances
• Interviews with experts on microfluidics - discover what authorities in that field think, say, and do, helping you stay ahead
• Analysis of what stimulates and restrains that industry and market - assess challenges and strengths, helping you compete and gain advantages
• Prospects for established players and companies entering that sector - explore needs, practices and outlooks for future success.

Information found nowhere else

That work gives independent analysis. You receive business intelligence found only in our report, seeing where prospects are most rewarding.

With our study you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.

Assess progress and potential in microfluidics now, seeing what you can gain.

Microfluidics - discover technological and commercial prospects by ordering now

Our study is for everyone investigating microfluidic technologies. There you find data, trends, opportunities, and sales predictions. Avoid missing out - please order our new report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6


Table of Contents

1. Executive Summary
1.1 Overview of Microfluidics Technology Market
1.2 Aim, Scope and Format of this Report
1.3 Chapters in the Report
1.4 Research and Analysis Methods
1.5 Glossary of Terms Relating to the Microfluidics Technology Market

2. Introduction to Microfluidics Technology
2.1 What is Microfluidics?
2.1.1 History of Microfluidics Technology
2.1.2 Continuous Flow Microfluidics
2.1.3 Digital Microfluidics
2.2 Benefits of Microfluidics Technology
2.3 Fabrication of Microfluidic Devices
2.4 Where Does Microfluidics Technology Find Applications?
2.5 The Microfluidic Technologies Market
2.5.1 Microfluidics Technology in the In Vitro Diagnostics Market
2.5.1.1 Clinical Diagnostics
2.5.1.2 Point of Care (POC) Diagnostics
2.5.1.3 Analytical Devices
2.5.2 Microfluidics Technology in Pharmaceutical and Life Science Research
2.5.2.1 Genomics
2.5.2.2 Proteomics
2.5.2.3 Cellular Assays
2.5.3 Microfluidics Technology in Drug Delivery
2.5.3.1 Increasing Popularity of Transdermal Drug Delivery
2.5.3.2 Microneedles
2.5.3.3 Micropumps
2.5.3.4 Inhalers
2.6 Regulation of Microfluidic Devices
2.6.1 The US Regulation System
2.6.2 Regulation of Laboratory Developed Tests
2.6.3 The European Regulatory System
2.6.3.1 Post Marketing Surveillance in the EU

3. The Global Microfluidic Technologies Market, 2013-2023
3.1 Microfluidic Technologies Market: Overview
3.2 Microfluidic Technologies Market by Segment, 2012
3.3 Microfluidic Technologies Market Forecast, 2013-2023
3.4 Microfluidic Technologies Market Trends, 2013-2023
3.4.1 Increase in Chronic Disease Patient Population
3.4.2 Shift towards Decentralisation
3.4.3 Increased Awareness through Globalisation
3.4.4 Growing Demand for Advanced Drug Delivery Methods
3.4.5 Microfluidics Technology Benefitting Biologics Market
3.4.6 Move towards Personalised Medicine
3.4.7 Fast Changing Market

4. Microfluidics Technology in the World In Vitro Diagnostics Market, 2013-2023
4.1 Microfluidics Based IVD Market: Overview
4.2 Microfluidics Based IVD Market by Segment, 2012
4.3 Microfluidics Based IVD Market Forecast, 2012-2017
4.4 Microfluidics Based IVD Market Forecast, 2017-2023
4.5 Microfluidics Based Clinical Diagnostics Market, 2012
4.5.1 Microfluidics Based Clinical Diagnostics Market Forecast, 2012-2023
4.6 Microfluidics Based POC Diagnostics Market, 2012
4.6.1 Microfluidics Based POC Diagnostics Market Forecast, 2012-2023
4.6.2 Leading Microfluidics Based POC Devices in the Market, 2013
4.6.3 Microfluidics Based POC Devices in Development, 2013
4.7 Microfluidics Based Analytical Devices Market, 2012
4.7.1 Microfluidics Based Analytical Devices Market Forecast, 2012-2023
4.7.2 Leading Microfluidics Based Analytical Devices in Market, 2013
4.8 Conclusions

5. Microfluidics Technology in Pharmaceutical and Life Science Research Market, 2013-2023
5.1 Microfluidics Based Pharmaceutical and Life Science Research Market: Overview
5.2 Microfluidics Based Pharmaceutical and Life Science Research Market by Segment, 2012
5.3 Microfluidics Based Pharmaceutical and Life Science Research Market Forecast, 2012-2017
5.4 Microfluidics Based Pharmaceutical and Life Science Research Market Forecast, 2017-2023
5.5 Microfluidics Based Genomics Market, 2012
5.5.1 Microfluidics Based Genomics Market Forecast, 2012-2023
5.6 Microfluidics Based Proteomics Market, 2012
5.6.1 Microfluidics Based Proteomics Market Forecast, 2012-2023
5.7 Microfluidics Based Cell-Based Assays Market, 2012
5.7.1 Microfluidics Based Cell-Based Assays Market Forecast, 2012-2023
5.8 Leading Microfluidics Based Pharmaceutical and Life Science Research Devices in Market, 2013
5.8.1 LabChip: A Highly Advanced Research Platform
5.8.2 2100 Bioanalyzer: Preferred Standard in a Research Lab
5.8.3 Microcapillary Protein Crystallisation System Plug Maker (Emerald Biosystems)
5.8.4 BioMark (Fluidigm Corporation)
5.8.5 C1 Single-Cell Auto Prep System (Fluidigm Corporation)
5.8.6 QX100ddPCR: A Leading Device in Digital PCR Technology
5.8.7 RainDrop System (RainDance Technologies)
5.8.8 Mondrian SP (NuGEN)
5.8.9 IonPGM Sequencer (Life Technologies)
5.8.10 Genome Analyzer (Illumina)
5.9 Conclusions

6. Microfluidics Technology in the Drug Delivery Market, 2013-2023
6.1 Microfluidics Based Drug Delivery Market: Overview
6.2 Market Projection for Microfluidics Based Drug Delivery Market, 2012-2023
6.3 Leading Microfluidics Based Drug Delivery Devices in Market, 2013
6.3.1 MiniMed Paradigm Revel System: A Leading Insulin Pump
6.3.2 MicronJet (Nanopass Technologies)
6.3.3 Nanoject: A Device for Intradermal Vaccine Delivery
6.3.4 Microstructured Transdermal System (MTS) Device
6.3.5 Respimat: A New Generation Inhaler
6.3.6 Spray Nozzles for Aerosol Inhaler Devices
6.4 Microfluidics Based Drug Delivery Devices in Development, 2013
6.4.1 Nanopump: A Miniaturised Drug Delivery Pump
6.4.2 JewelPUMP: Hoping to Revolutionise the Life of Diabetic Patients
6.4.3 SOLO Micropump: Smallest and Lightest Insulin Pump
6.4.4 AdminPen: New Liquid Injection System
6.4.5 PKA SoftTouch Microneedle: Breakthrough from PKA SoftTouch Corp?
6.4.6 DrugMAT: Microneedle Patch for Drug/Vaccine Delivery
6.4.7 MicroCor: Minimally Invasive Drug/Vaccine Delivery System
6.4.8 Implantable Drug Delivery Device
6.5 Conclusions

7. Leading National Microfluidic Technologies Markets, 2013-2023
7.1 Regional Breakdown of the Microfluidic Technologies Market, 2012
7.2 Microfluidic Technologies Market: Regional Forecast 2012-2023
7.3 The US 2012-2023: Leading National Market
7.4 Europe 2012-2023: Analysis of EU5
7.4.1 Germany 2012-2023: Largest European Market
7.4.2 France 2012-2023: Patient Demographics will Push Market Growth
7.4.3 Italy 2012-2023: Slow Growth Owing to Economic Crisis
7.4.4 Spain 2012-2023: Facing Cost Containment Measures
7.4.5 UK 2012-2023: Budgetary Constraints
7.5 Japan 2012-2023: Second Largest National Market in 2012
7.6 China 2012-2023: Potential for Strong Growth
7.7 India 2012-2023: Fastest Growing National Market

8. Leading Companies in the Microfluidic Technologies Industry, 2013
8.1 Agilent Technologies
8.1.1 Sales and Performance Analysis, 2012
8.1.2 Diagnostics and Genomics Business Analysis, 2012
8.1.3 Sales and Performance Analysis by Region, 2012
8.2 PerkinElmer
8.2.1 Sales and Performance Analysis, 2012
8.2.2 Human Health Segment Analysis, 2012
8.3 Cepheid
8.3.1 Sales and Performance Analysis, 2012
8.3.2 Product Sales by Category, 2012
8.3.3 Product Sales by Region, 2012
8.4 Fluidigm Corporation
8.4.1 Sales and Performance Analysis, 2012
8.4.2 Product Sales Analysis by Segment, 2012
8.4.3 Product Sales by Region, 2012
8.5 Other Companies, 2013

9. SWOT Analysis of the Microfluidic Technologies Market, 2013-2023
9.1 Strengths
9.1.1 Increase in Prevalence of Diseases Worldwide
9.1.2 Ability to Fit an Entire Lab on to a Chip
9.1.3 Wide Range of Biological Applications
9.2 Weaknesses
9.2.1 Microfluidics Remains an Emerging Field
9.2.2 The Gap between Academia and Industry
9.2.3 Limited Adoption of Microfluidics Technology
9.3 Opportunities
9.3.1 Growth of Personalised Medicine
9.3.2 Microfluidic Devices for Stem Cell Research
9.3.3 Point of Care Diagnostics Poised for Strong Growth
9.3.4 Expansion into Developing National Markets
9.4 Threats
9.4.1 Complexity of Microfluidic Devices Posing Regulatory Challenges
9.4.2 Lack of Sufficient Healthcare Coverage
9.4.3 Medical Device Excise Tax

10. Research Interviews
10.1 Interview with CYTOO Cell Architects
10.1.1 The Current State of the Microfluidics Technology Market
10.1.2 Role of Microfluidics in Cell-Based Assays
10.1.3 Major Challenges Faced by Microfluidics Technology
10.1.4 The Outlook for Microfluidics Technology
10.2 Interview with GeneFluidics
10.2.1 About GeneFluidics
10.2.2 Microfluidics Technology Market Environment
10.2.3 Impact of Microfluidics Technology on Personalised Medicine
10.2.4 Obstacles to Market Growth

11. Conclusions of the Study
11.1 The Microfluidic Technologies Market, 2013-2023
11.2 The IVD Market
11.3 The Pharmaceutical and Life Science Research Market
11.4 The Drug Delivery Market
11.5 Concluding Remarks



List of Tables

Table 3.1 Microfluidic Technologies Market: Sales ($m) and Market Shares (%) by Segment, 2012
Table 3.2 Microfluidic Technologies Market Forecast ($m, %) by Segment, 2012-2017
Table 3.3 Microfluidic Technologies Market Forecast ($m, %) by Segment, 2017-2023
Table 3.4 Key Mergers and Acquisitions in the Microfluidic Technologies Market, 2011
Table 4.1 Microfluidics Based IVD Market: Sales ($m) and Market Shares (%), 2012
Table 4.2 Microfluidics Based IVD Market Forecast ($m, %), 2012-2017
Table 4.3 Microfluidics Based IVD Market Forecast ($m, %), 2017-2023
Table 4.4 Microfluidics Based Clinical Diagnostics: Market Forecast ($m, %), 2012-2017
Table 4.5 Microfluidics Based Clinical Diagnostics: Market Forecast ($m, %), 2017-2023
Table 4.6 Microfluidics Based POC Diagnostics: Market Forecast ($m, %), 2012-2017
Table 4.7 Microfluidics Based POC Diagnostics: Market Forecast ($m, %), 2017-2023
Table 4.8 Leading Microfluidics Based POC Devices in the Market, 2013
Table 4.9 Microfluidics Based POC Devices in Development, 2013
Table 4.10 Microfluidics Based Analytical Devices: Market Forecast ($m, %), 2012-2017
Table 4.11 Microfluidics Based Analytical Devices: Market Forecast ($m, %), 2017-2023
Table 4.12 Leading Microfluidics Based Analytical Devices in the Market, 2013
Table 5.1 Microfluidics Based Pharmaceutical and Life Science Research Market: Sales ($m) and Market Shares (%) by Segment, 2012
Table 5.2 Microfluidics Based Pharmaceutical and Life Science Research Market Forecast ($m, %) by Segment, 2012-2017
Table 5.3 Microfluidics Based Pharmaceutical and Life Science Research Market Forecast ($m, %) by Segment, 2017-2023
Table 5.4 Microfluidics Based Genomics Market Forecast ($m, %), 2012-2017
Table 5.5 Microfluidics Based Genomics Market Forecast ($m, %), 2017-2023
Table 5.6 Microfluidics Based Proteomics Market Forecast ($m, %), 2012-2017
Table 5.7 Microfluidics Based Proteomics Market Forecast ($m, %), 2017-2023
Table 5.8 Microfluidics Based Cell-Based Assay Market Forecast ($m, %), 2012-2017
Table 5.9 Microfluidics Based Cell-Based Assay Market Forecast ($m, %), 2017-2023
Table 5.10 Leading Microfluidics Based Pharmaceutical and Life Science Research Devices in Market, 2013
Table 6.1 Microfluidics Based Drug Delivery: Market Forecast ($m, %), 2012-2017
Table 6.2 Microfluidics Based Drug Delivery: Market Forecast ($m, %), 2017-2023
Table 6.3 Leading Microfluidics Based Drug Delivery Devices in the Market, 2013
Table 6.4 Microfluidics Based Drug Delivery Devices in Development, 2013
Table 7.1 Leading National Microfluidic Technologies Market: Sales ($m) and Market Shares (%), 2012
Table 7.2 Microfluidic Technologies: Market Forecasts ($m, %) by Leading Country, 2012-2017
Table 7.3 Microfluidic Technologies: Market Forecasts ($m, %) by Leading Country, 2017-2023
Table 7.4 European Microfluidic Technology Markets: Sales ($m) and Market Shares (%) in Leading National Markets, 2012
Table 7.5 European Microfluidic Technology Markets: Forecasts ($m, %) by Leading Country, 2012-2017
Table 7.6 European Microfluidic Technology Markets: Forecasts ($m, %) by Leading Country, 2017-2023
Table 8.1 Agilent Technologies: Net Revenue ($bn) and Revenue Shares (%) by Business Group, 2012
Table 8.2 Agilent Technologies: Net Revenue ($bn) and Revenue Shares (%) by Region, 2012
Table 8.3 PerkinElmer: Revenue ($bn) and Revenue Shares (%) by Segment, 2012
Table 8.4 Cepheid: Revenue ($m) and Revenue Shares (%) by Segment, 2012
Table 8.5 Cepheid: Revenue ($m) and Revenue Shares (%) by Product Category, 2012
Table 8.6 Cepheid: Revenue ($m) and Revenue Shares (%) by Region, 2012
Table 8.7 Fluidigm Corporation: Revenue ($m) and Revenue Shares (%) by Segment, 2012
Table 8.8 Fluidigm Corporation: Revenue ($m) and Revenue Shares (%) by Product Segment, 2012
Table 8.9 Fluidigm Corporation: Revenue ($m) and Revenue Shares (%) of Products by Region, 2012
Table 8.10 Other Companies in the Microfluidic Technologies Market, 2013
Table 9.1 SWOT Analysis of the Microfluidic Technologies Market, 2013
Table 11.1 Segments in the Microfluidic Technologies Market: Sales ($m) in 2012, 2017, 2019 and 2023



List of Figures

Figure 3.1 Microfluidic Technologies Market: Sales ($m) by Segment, 2012
Figure 3.2 Microfluidic Technologies Market: Market Shares (%) by Segment, 2012
Figure 3.3 Microfluidic Technologies Market Forecast ($m), 2012-2023
Figure 3.4 Microfluidic Technologies Market Forecasts ($m) by Segment, 2012-2023
Figure 4.1 Microfluidics Based IVD Market: Sales ($m) by Segment, 2012
Figure 4.2 Microfluidics Based IVD Market: Market Shares (%) by Segment, 2012
Figure 4.3 Microfluidics Based IVD Market Forecast ($m), 2012-2023
Figure 4.4 Microfluidics Based Clinical Diagnostics Market Forecast ($m), 2012-2023
Figure 4.5 Microfluidics Based POC Diagnostics Market Forecast ($m), 2012-2023
Figure 4.6 Microfluidics Based Analytical Devices Market Forecast, 2012-2023
Figure 5.1 Microfluidics Based Pharmaceutical and Life Science Research Market: Sales ($m) by Segment, 2012
Figure 5.2 Microfluidics Based Pharmaceutical and Life Science Research Market: Market Shares (%) by Segment, 2012
Figure 5.3 Microfluidics Based Pharmaceutical and Life Science Research Market Forecast ($m), 2012-2023
Figure 5.4 Microfluidics Based Genomics Market Forecast ($m), 2012-2023
Figure 5.5 Microfluidics Based Proteomics Market Forecast ($m), 2012-2023
Figure 5.6 Microfluidics Based Cell-Based Assay Market Forecast ($m), 2012-2023
Figure 6.1 Microfluidics Based Drug Delivery Market Forecast ($m), 2012-2023
Figure 7.1 Microfluidic Technology Market: Sales ($m) in Leading National Markets, 2012
Figure 7.2 Microfluidic Technology Market: Market Shares (%) in Leading National Markets, 2012
Figure 7.3 The US Microfluidic Technology Market Forecast ($m), 2012-2023
Figure 7.4 The European Microfluidic Technology Markets: Sales ($m) in Leading National Markets, 2012
Figure 7.5 The European Microfluidic Technology Markets: Market Shares (%) in Leading National Markets, 2012
Figure 7.6 The European Microfluidic Technology Market Forecast ($m), 2012-2023
Figure 7.7 The German Microfluidic Technology Market Forecast ($m), 2012-2023
Figure 7.8 The French Microfluidic Technology Market Forecast ($m), 2012-2023
Figure 7.9 The Italian Microfluidic Technology Market Forecast ($m), 2012-2023
Figure 7.10 The Spanish Microfluidic Technology Market Forecast ($m), 2012-2023
Figure 7.11 The UK Microfluidic Technology Market Forecast ($m), 2012-2023
Figure 7.12 The Japanese Microfluidic Technology Market Forecast ($m), 2012-2023
Figure 7.13 The Chinese Microfluidic Technology Market Forecast ($m), 2012-2023
Figure 7.14 The Indian Microfluidic Technology Market Forecast ($m), 2012-2023
Figure 8.1 Agilent Technologies: Net Revenue ($bn) by Business Group, 2012
Figure 8.2 Agilent Technologies: Revenue Shares (%) by Business Group, 2012
Figure 8.3 Agilent Technologies: Revenue Shares (%) by Region, 2012
Figure 8.4 PerkinElmer: Revenue Shares (%) by Segment, 2012
Figure 8.5 Cepheid: Revenue ($m) by Segment, 2012
Figure 8.6 Cepheid: Revenue Shares (%) by Segment, 2012
Figure 8.7 Cepheid: Revenue ($m) by Product Category, 2012
Figure 8.8 Cepheid: Revenue Shares (%) by Product Category, 2012
Figure 8.9 Cepheid: Revenue Shares (%) by Region, 2012
Figure 8.10 Fluidigm Corporation: Revenue Shares (%) by Segment, 2012
Figure 8.11 Fluidigm Corporation: Revenue ($m) by Product Segment, 2012
Figure 8.12 Fluidigm Corporation: Revenue Shares (%) by Product Segment, 2012
Figure 8.13 Fluidigm Corporation: Revenue Shares (%) of Products by Region, 2012
Figure 11.1 Microfluidic Technologies Market: Sales ($m) in 2012, 2017, 2019 and 2023
Figure 11.2 Segments in the Microfluidic Technologies Market: Sales ($m) in 2012, 2017, 2019 and 2023



Companies Listed

3M
Abaxis
Abbott
Achira Labs
Advalytix
Advanced Liquid Logic
Advion
AES Laboratoire
Affymetrix
Agilent Technologies
Akkonni Biosystems
Alere
American Heart Association and American College of Cardiology (AHA/ACC)
Applied Biophysics
Arcxis Biotechnologies
Artemis Health
Atonomics
Axis-Shield
BaiO
Beckman Coulter
Becton Dickinson
BellBrook Laboratories
Biocius
Biodetection Instruments
Biodot
Biofluidix
BioForce Nanosciences
Biolithic
Bionas
Bio-Rad Laboratories
Bioscale
Biosite
Biosurfit
BioTray
Biotrove
BioVitesse
Boehringer Ingelheim
Boston Microfluidics
California Institute of Regenerative Medicine (CIRM)
Caliper Life Sciences
Cambridge Biomagnetics
Capilix
CapitalBio Corporation
CEA Laboratory of Electronics and Information Technologies (LETI)
Cellanyx
Cellasic
Cellectricon
Cellix
Celula
Center for Devices and Radiological Health (CDRH)
Cepheid
Cetoni
Claros Diagnostics
ClonDiag
Corium International
Crospon
Cyclofluidic
Cynvenio
CYTOO Cell Architects
Dako
Daktari Diagnostics
Dalian Institute of Chemical Physics (DICP)
Danaher
Debiotech
Diagnostics For All
Digilab Global
DNA Electronics
Dolomite Microfluidics
Eksigent Technologies
Emerald Biosystems
Epigem
Epocal
Fluidigm Corporation
Fluidmedix
Fluidware Technologies
Fluxion Biosciences
FocusDx
Food and Drug Administration (FDA)
GE Healthcare
GeneFluidics
GeneWave
Geniachip
GnuBio
Gyros
Habsel
Hain Lifesciences
Handylab
Helicos Biosciences
Hewlett Packard
IBM
Idaho Technologies
Illumina
IMEC
Incept BioSystems
Indian Institute of Technology (IIT)
Infineon AG
Innogenetics NV
Inostics
Institute of MicroAnalytical Technology (IMAS)
IonTorrent
IQuum
Janssen Pharmaceuticals
Lab901
Labcyte
labNow
Labsmith
LC Sciences
LeukoDx
Life Technologies
Massachusetts Institute of Technology
Mbio Diagnostics
Medimate
Medingo
Medspray
Medtronic
Micro/Nano Fluidics Focus (MF3) Centre
Micro2Gen
MicroCHIPS
Micronics
Micronit
MicroTEC
Micrux Technologies
Millipore
Mode Diagnostics
Molecular Vision
Mycrolab
Nanion Technologies
nanoBiosciences
Nanobiosym
NanoEnTek
Nanogen
Nanomix
Nanopass Technologies
Nanopoint Imaging
Nanosphere
NanoTerra
National Health Service (NHS)
National Institutes of Health (NIH)
Nemaura Pharma
Novartis
NuGEN
On-Q-ity
Opko Diagnostics
Osmotex
Panasonic
Pathogenetix
PerkinElmer
Philips
PKA SoftTouch Corp
PositiveID Corporation
Procter & Gamble
Proteus Biomedical
Qiagen
QuantaLife
QuantumMDX
Quest
Quorum Technologies
RainDance Technologies
Rheonix
Roche
Samsung
Scienion
Sensimed
SensiVida Medical Technologies
SFC Fluidics
Shanghai BioChip
Shanghai Institute of Microsystem and Information Technology (SIMIT)
Siemens
Silicon Biosystems
Siloam Biosciences
Singapore Economic Development Board (EDB)
SlipChip LLC
Sony
Spartan Bioscience
Sphere Medical
Stanford University
STMicroelectronics
SurModics
TearLab
TECAN
TheraJect Inc
Thermo Fisher Scientific
Triversa Nanomate
Tufts Center for the Study of Drug Development
UFluidix
United Gene
University of Tokyo
Veridex
Vivacta
Wasatch Microfluidics
Wave 80 Biosciences
World Health Organization (WHO)
Xona Microfluidics
Yulong




Read the full report:
Microfluidic Technologies: Biopharmaceutical and Healthcare Applications 2013-2023
http://www.reportbuyer.com/pharma_healthcare/diagnostics/microfluidic_te...

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

 

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In their session at 17th Cloud Expo, Hal Schwartz, CEO of Secure Infrastructure & Services (SIAS), and Chuck Paolillo, CTO of Secure Infrastructure & Services (SIAS), provide a study of cloud adoption trends and the power and flexibility of IBM Power and Pureflex cloud solutions. In his role as CEO of Secure Infrastructure & Services (SIAS), Hal Schwartz provides leadership and direction for the company.
There are many considerations when moving applications from on-premise to cloud. It is critical to understand the benefits and also challenges of this migration. A successful migration will result in lower Total Cost of Ownership, yet offer the same or higher level of robustness. In his session at 15th Cloud Expo, Michael Meiner, an Engineering Director at Oracle, Corporation, analyzed a range of cloud offerings (IaaS, PaaS, SaaS) and discussed the benefits/challenges of migrating to each offe...
SYS-CON Events announced today that the "Second Containers & Microservices Expo" will take place November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Containers and microservices have become topics of intense interest throughout the cloud developer and enterprise IT communities.
As organizations shift towards IT-as-a-service models, the need for managing and protecting data residing across physical, virtual, and now cloud environments grows with it. CommVault can ensure protection and E-Discovery of your data – whether in a private cloud, a Service Provider delivered public cloud, or a hybrid cloud environment – across the heterogeneous enterprise. In his session at 17th Cloud Expo, Randy De Meno, Chief Technologist - Windows Products and Microsoft Partnerships at Com...
The Software Defined Data Center (SDDC), which enables organizations to seamlessly run in a hybrid cloud model (public + private cloud), is here to stay. IDC estimates that the software-defined networking market will be valued at $3.7 billion by 2016. Security is a key component and benefit of the SDDC, and offers an opportunity to build security 'from the ground up' and weave it into the environment from day one. In his session at 16th Cloud Expo, Reuven Harrison, CTO and Co-Founder of Tufin,...
Scrum Alliance has announced the release of its 2015 State of Scrum Report. Almost 5,000 individuals and companies worldwide participated in this year's survey. Most organizations in the market today are still leading and managing under an Industrial Age model. Not only is the speed of change growing exponentially, Agile and Scrum frameworks are showing companies how to draw on the full talents and capabilities of those doing the work in order to continue innovating for success.
SYS-CON Events announced today that MobiDev, a software development company, will exhibit at the 17th International Cloud Expo®, which will take place November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software development company with representative offices in Atlanta (US), Sheffield (UK) and Würzburg (Germany); and development centers in Ukraine. Since 2009 it has grown from a small group of passionate engineers and business managers to a full-scale mobi...
Between the compelling mockups and specs produced by your analysts and designers, and the resulting application built by your developers, there is a gulf where projects fail, costs spiral out of control, and applications fall short of requirements. In his session at @DevOpsSummit, Charles Kendrick, CTO and Chief Architect at Isomorphic Software, presented a new approach where business and development users collaborate – each using tools appropriate to their goals and expertise – to build mocku...
Container technology is sending shock waves through the world of cloud computing. Heralded as the 'next big thing,' containers provide software owners a consistent way to package their software and dependencies while infrastructure operators benefit from a standard way to deploy and run them. Containers present new challenges for tracking usage due to their dynamic nature. They can also be deployed to bare metal, virtual machines and various cloud platforms. How do software owners track the usag...
SYS-CON Events announced today that VividCortex, the monitoring solution for the modern data system, will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. The database is the heart of most applications, but it’s also the part that’s hardest to scale, monitor, and optimize even as it’s growing 50% year over year. VividCortex is the first unified suite of database monitoring tools specifically desi...
Graylog, Inc., has added the capability to collect, centralize and analyze application container logs from within Docker. The Graylog logging driver for Docker addresses the challenges of extracting intelligence from within Docker containers, where most workloads are dynamic and log data is not persisted or stored. Using Graylog, DevOps and IT Ops teams can pinpoint the root cause of problems to deliver new applications faster and minimize downtime.
As Marc Andreessen says software is eating the world. Everything is rapidly moving toward being software-defined – from our phones and cars through our washing machines to the datacenter. However, there are larger challenges when implementing software defined on a larger scale - when building software defined infrastructure. In his session at 16th Cloud Expo, Boyan Ivanov, CEO of StorPool, provided some practical insights on what, how and why when implementing "software-defined" in the datacent...
Learn how you can use the CoSN SEND II Decision Tree for Education Technology to make sure that your K–12 technology initiatives create a more engaging learning experience that empowers students, teachers, and administrators alike.
Mobile, social, Big Data, and cloud have fundamentally changed the way we live. “Anytime, anywhere” access to data and information is no longer a luxury; it’s a requirement, in both our personal and professional lives. For IT organizations, this means pressure has never been greater to deliver meaningful services to the business and customers.
In a recent research, analyst firm IDC found that the average cost of a critical application failure is $500,000 to $1 million per hour and the average total cost of unplanned application downtime is $1.25 billion to $2.5 billion per year for Fortune 1000 companies. In addition to the findings on the cost of the downtime, the research also highlighted best practices for development, testing, application support, infrastructure, and operations teams.